Susquehanna International Group
DNLI icon

Susquehanna International Group’s Denali Therapeutics DNLI Stock Holding History

Susquehanna International Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.5M Buy
130,100
+96,100
+283% +$1.91M ﹤0.01% 5652
2025
Q4 		$561K Sell
34,000
-40,500
-54% -$684K ﹤0.01% 8497
2025
Q3 		$1.08M Buy
74,500
+36,100
+94% +$519K ﹤0.01% 7176
2025
Q2 		$537K Buy
+38,400
New +$540K ﹤0.01% 9013
2025
Q1 		– Sell
-13,700
Closed -$279K – 12669
2024
Q4 		$279K Buy
13,700
+500
+4% +$12.8K ﹤0.01% 9987
2024
Q3 		$385K Buy
13,200
+700
+6% +$17.4K ﹤0.01% 9075
2024
Q2 		$290K Sell
12,500
-5,900
-32% -$113K ﹤0.01% 9515
2024
Q1 		$378K Buy
18,400
+7,900
+75% +$148K ﹤0.01% 9159
2023
Q4 		$225K Sell
10,500
-6,500
-38% -$129K ﹤0.01% 10432
2023
Q3 		$351K Buy
17,000
+8,800
+107% +$223K ﹤0.01% 9019
2023
Q2 		$242K Sell
8,200
-6,900
-46% -$194K ﹤0.01% 9879
2023
Q1 		$348K Sell
15,100
-13,300
-47% -$366K ﹤0.01% 9403
2022
Q4 		$790K Sell
28,400
-16,900
-37% -$503K ﹤0.01% 6705
2022
Q3 		$1.39M Buy
45,300
+22,400
+98% +$728K ﹤0.01% 5767
2022
Q2 		$674K Buy
22,900
+8,200
+56% +$215K ﹤0.01% 7527
2022
Q1 		$473K Buy
14,700
+400
+3% +$13.8K ﹤0.01% 9135
2021
Q4 		$638K Sell
14,300
-27,100
-65% -$1.28M ﹤0.01% 8498
2021
Q3 		$2.09M Buy
41,400
+7,100
+21% +$400K ﹤0.01% 5736
2021
Q2 		$2.69M Sell
34,300
-7,700
-18% -$476K ﹤0.01% 5269
2021
Q1 		$2.4M Sell
42,000
-105,100
-71% -$7.04M ﹤0.01% 5470
2020
Q4 		$12.3M Buy
147,100
+126,600
+618% +$7.65M ﹤0.01% 2258
2020
Q3 		$735K Sell
20,500
-13,400
-40% -$404K ﹤0.01% 6858
2020
Q2 		$820K Buy
+33,900
New +$797K ﹤0.01% 6339
2020
Q1 		– Sell
-37,900
Closed -$660K – 10348
2019
Q4 		$660K Sell
37,900
-17,500
-32% -$291K ﹤0.01% 6385
2019
Q3 		$849K Buy
55,400
+5,800
+12% +$111K ﹤0.01% 6059
2019
Q2 		$1.03M Buy
+49,600
New +$1.11M ﹤0.01% 5585

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's DNLI Position: Q1 2026 in Review

Susquehanna International Group increased its Denali Therapeutics (DNLI) stake by 45% in Q1 2026, buying an estimated $313K and bringing the position to 50,475 shares worth $969K. The position accounts for ﹤0.01% of the portfolio, ranked #7967.

Susquehanna International Group first reported a position in DNLI in Q2 2019 and has held it in 27 quarters since. The position peaked at $7.85M in Q1 2023. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Susquehanna International Group held 50,475 shares of Denali Therapeutics worth $969K as of Q1 2026.
  • Susquehanna International Group bought 15,707 Denali Therapeutics shares in Q1 2026, an estimated $313K.
  • Denali Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7967 holding.
  • Susquehanna International Group first reported a position in Denali Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Susquehanna International Group's Denali Therapeutics position peaked at $7.85M in Q1 2023.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.